Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Inclusion Criteria:

   - Participant has histologically confirmed diagnosis of high-grade serous or high-grade
   endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

   - Measurable disease, i.e., at least one measurable lesion per RECIST 1.1 criteria (a
   lesion at a previously irradiated site may only be counted as a target lesion if there
   is clear sign of progression since the irradiation)

   - If no measurable disease is present, the disease should be assessable by Gynecologic
   Cancer Intergroup criteria (GCIC) for CA-125

   - Participant has no germline BRCA1/2 mutation as determined by an FDA approved assay.

   - Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
   or 1

   - Participant has platinum-resistant (progression within one to six months after
   completing platinum-based therapy) or platinum refractory disease (progression during
   treatment or within 4 weeks after the last dose), where platinum-based therapy is not
   an option, according to the GCIG 5th Ovarian Cancer Consensus Conference definitions.
   The platinum-based chemotherapy regimen does not necessarily need to be the last
   regimen the participant received prior to study entry.

   - Participant must have received at least one but no more than three prior systemic
   treatment regimens and for whom single-agent chemotherapy is appropriate as the next
   line of treatment.

   - Participant has adequate bone marrow and organ function

Exclusion Criteria:

   - Participant has received prior treatment with any PI3K, mTOR or AKT inhibitor.

   - Participant is concurrently using other anti-cancer therapy

   - Participant is in a state of small or large bowel obstruction or has other impairment
   of gastrointestinal (GI) function or GI disease

   - Participant has had surgery within 14 days prior to starting study drug or has not
   recovered from major side effects

   - Participant has not recovered from all toxicities 5 related to prior anticancer
   therapies to baseline or NCI CTCAE Version 4.03 Grade ≤1. Exception to this criterion:
   participants with any grade of alopecia are allowed to enter the study.

   - Participants with liver impairment and Child Pugh score B or C

   - Participant has received radiotherapy ≤ 4 weeks or limited field radiation for
   palliation ≤2 weeks prior to randomization, and who has not recovered to baseline,
   grade 1 or better from related side effects of such therapy (with the exception of
   alopecia).

   - Participant has a known hypersensitivity to any of the study drugs or excipients

Other inclusion/exclusion criteria may apply